Q1 EPS Forecast for Tonix Pharmaceuticals Boosted by Analyst

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) – Noble Financial upped their Q1 2026 earnings per share estimates for shares of Tonix Pharmaceuticals in a research report issued to clients and investors on Monday, March 16th. Noble Financial analyst R. Leboyer now forecasts that the company will post earnings per share of ($2.06) for the quarter, up from their previous estimate of ($2.60). The consensus estimate for Tonix Pharmaceuticals’ current full-year earnings is ($1,762.50) per share. Noble Financial also issued estimates for Tonix Pharmaceuticals’ Q2 2026 earnings at ($2.07) EPS, Q3 2026 earnings at ($2.21) EPS, Q4 2026 earnings at ($2.38) EPS and FY2026 earnings at ($8.72) EPS.

Tonix Pharmaceuticals (NASDAQ:TNXP) last posted its earnings results on Thursday, March 12th. The company reported ($3.98) earnings per share for the quarter, missing the consensus estimate of ($3.16) by ($0.82). The business had revenue of $5.39 million for the quarter, compared to analysts’ expectations of $2.97 million. Tonix Pharmaceuticals had a negative return on equity of 60.15% and a negative net margin of 946.22%.

Other research analysts also recently issued reports about the stock. Wall Street Zen raised shares of Tonix Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, January 17th. Weiss Ratings reissued a “sell (e+)” rating on shares of Tonix Pharmaceuticals in a research report on Wednesday, January 21st. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold”.

Tonix Pharmaceuticals Trading Up 11.1%

TNXP stock opened at $15.77 on Wednesday. The stock has a market cap of $211.40 million, a P/E ratio of -1.11 and a beta of 1.88. Tonix Pharmaceuticals has a twelve month low of $13.07 and a twelve month high of $69.97. The company’s 50 day moving average is $15.59 and its two-hundred day moving average is $18.55.

Hedge Funds Weigh In On Tonix Pharmaceuticals

A number of institutional investors have recently modified their holdings of TNXP. Legal & General Group Plc purchased a new stake in Tonix Pharmaceuticals in the 2nd quarter valued at $25,000. Ameritas Investment Partners Inc. purchased a new position in Tonix Pharmaceuticals during the 2nd quarter worth $28,000. Russell Investments Group Ltd. acquired a new position in Tonix Pharmaceuticals in the third quarter valued at $29,000. Police & Firemen s Retirement System of New Jersey acquired a new position in Tonix Pharmaceuticals in the second quarter valued at $62,000. Finally, State of Wyoming purchased a new stake in shares of Tonix Pharmaceuticals in the fourth quarter valued at about $27,000. 82.26% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Tonix Pharmaceuticals

In other news, CEO Seth Lederman acquired 15,000 shares of the firm’s stock in a transaction dated Wednesday, March 18th. The stock was acquired at an average cost of $14.89 per share, with a total value of $223,350.00. Following the completion of the acquisition, the chief executive officer owned 15,001 shares of the company’s stock, valued at $223,364.89. The trade was a 1,500,000.00% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 0.03% of the company’s stock.

Trending Headlines about Tonix Pharmaceuticals

Here are the key news stories impacting Tonix Pharmaceuticals this week:

• Positive Sentiment: CEO Seth Lederman bought 15,000 shares at roughly $14.89, a meaningful insider purchase that signals management confidence and often supports investor sentiment. Read More.
• Positive Sentiment: Tonix will present at BIO‑Europe Spring (Mar 24), giving management exposure to potential partners and investors; such conference presentations can boost business‑development visibility and near‑term interest. Read More.
• Positive Sentiment: The company also announced AACR 2026 oral/poster presentations on its preclinical immuno‑oncology programs, which could add scientific validation and partnership upside if data are well‑received. Read More.
• Neutral Sentiment: Q4 results were mixed: revenue beat consensus but EPS missed, pointing to early commercial traction for products yet continued margin and profitability pressure — investors will be watching guidance and cash‑runway commentary. Read More.
• Neutral Sentiment: Institutional ownership is high and some large funds have recently added positions, which can amplify moves (both up and down) as block trades and flows occur. Read More.
• Negative Sentiment: Noble Financial revised several FY/Qtr EPS forecasts, increasing the projected full‑year loss and cutting some quarterly estimates — analyst downgrades and wider loss expectations can weigh on sentiment despite positive headlines. Read More.

Tonix Pharmaceuticals Company Profile

Tonix Pharmaceuticals is a clinical-stage biotechnology company focused on developing therapeutics for central nervous system disorders, immunology and rare diseases. The company’s pipeline includes small-molecule and biologic product candidates designed to address conditions such as fibromyalgia, post-traumatic stress disorder (PTSD) and other chronic pain syndromes, as well as vaccines for potential viral and biothreat agents.

Among Tonix’s lead programs is TNX-102 SL, a sublingual formulation of cyclobenzaprine being evaluated for the treatment of fibromyalgia and PTSD.